期刊
LEUKEMIA & LYMPHOMA
卷 55, 期 7, 页码 1451-1462出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2013.845883
关键词
Myeloid leukemias and dysplasias; tyrosine kinase inhibitor; drug resistance
资金
- Novartis Pharmaceuticals Corporation
Despite vast improvements in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase (CP), advanced stages of CML, accelerated phase or blast crisis, remain notoriously difficult to treat. Treatments that are highly effective against CML-CP produce disappointing results against advanced disease. Therefore, a primary goal of therapy should be to maintain patients in CP for as long as possible, by (1) striving for deep, early molecular response to treatment; (2) using tyrosine kinase inhibitors that lower risk of disease progression; and (3) more closely observing patients who demonstrate cytogenetic risk factors at diagnosis or during treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据